Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.33 |
| ▸ | ITGAV | P06756 | 2/20 | 0.33 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080646 | 0.85 | ITGAV (0.33) | AGTR1AGTR2ITGAVITGA2ALOX5 | |
| SCHEMBL7083342 | 0.83 | RAPGEF3 (0.37) | AGTR1AGTR2LTA4H | |
| SCHEMBL7077441 | 0.83 | AGTR1 (0.33) | AGTR1AGTR2ALOX5CYP3A4CYP2C19 | |
| SCHEMBL7080333 | 0.82 | GRM2 (0.41) | CYP3A4SMN1; SMN2 | |
| SCHEMBL7076731 | 0.74 | RAPGEF3 (0.43) | LTA4HSMN1; SMN2 | |
| SCHEMBL7083371 | 0.73 | AGTR1 (0.33) | AGTR1AGTR2LTA4HADORA2AADORA1 | |
| SCHEMBL7080257 | 0.72 | PTGS2 (0.38) | CYP3A4SMN1; SMN2 | |
| SCHEMBL7744231 | 0.63 | CASP1 (0.51) | L3MBTL1 | |
| SCHEMBL7048489 | 0.63 | POLB (0.43) | AGTR1AGTR2 | |
| SCHEMBL29165186 | 0.63 | CA9 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | CETP 120/4885AGTR1 845/4885AGTR2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.